FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097158220> ?p ?o ?g. }

• W3097158220 endingPage "262" @default.
• W3097158220 startingPage "243" @default.
• W3097158220 abstract "To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa). The panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence. A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment. The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management. Updated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them." @default.
• W3097158220 created "2020-11-09" @default.
• W3097158220 creator A5002985141 @default.
• W3097158220 creator A5004091567 @default.
• W3097158220 creator A5009101766 @default.
• W3097158220 creator A5011133286 @default.
• W3097158220 creator A5013864806 @default.
• W3097158220 creator A5018595176 @default.
• W3097158220 creator A5019052630 @default.
• W3097158220 creator A5019998379 @default.
• W3097158220 creator A5020731291 @default.
• W3097158220 creator A5021804435 @default.
• W3097158220 creator A5023131151 @default.
• W3097158220 creator A5023266580 @default.
• W3097158220 creator A5030545703 @default.
• W3097158220 creator A5032518609 @default.
• W3097158220 creator A5036460810 @default.
• W3097158220 creator A5053854071 @default.
• W3097158220 creator A5056479059 @default.
• W3097158220 creator A5060396380 @default.
• W3097158220 creator A5063466486 @default.
• W3097158220 creator A5067177119 @default.
• W3097158220 creator A5075410399 @default.
• W3097158220 creator A5075511405 @default.
• W3097158220 creator A5075546358 @default.
• W3097158220 creator A5078216208 @default.
• W3097158220 creator A5080627838 @default.
• W3097158220 creator A5081598999 @default.
• W3097158220 creator A5089586523 @default.
• W3097158220 date "2021-02-01" @default.
• W3097158220 modified "2023-10-18" @default.
• W3097158220 title "EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent" @default.
• W3097158220 cites W1076742793 @default.
• W3097158220 cites W1477301283 @default.
• W3097158220 cites W1489963450 @default.
• W3097158220 cites W1499310009 @default.
• W3097158220 cites W1526199464 @default.
• W3097158220 cites W1553544812 @default.
• W3097158220 cites W1571792083 @default.
• W3097158220 cites W1579723599 @default.
• W3097158220 cites W1593604458 @default.
• W3097158220 cites W1749926766 @default.
• W3097158220 cites W1827911007 @default.
• W3097158220 cites W1835600783 @default.
• W3097158220 cites W1835835741 @default.
• W3097158220 cites W1864240211 @default.
• W3097158220 cites W1961348267 @default.
• W3097158220 cites W1968339106 @default.
• W3097158220 cites W1968400906 @default.
• W3097158220 cites W1977970364 @default.
• W3097158220 cites W1978229612 @default.
• W3097158220 cites W1980053751 @default.
• W3097158220 cites W1985587689 @default.
• W3097158220 cites W1987796424 @default.
• W3097158220 cites W2000445173 @default.
• W3097158220 cites W2000764344 @default.
• W3097158220 cites W2001276593 @default.
• W3097158220 cites W2001616768 @default.
• W3097158220 cites W2003473186 @default.
• W3097158220 cites W2011335777 @default.
• W3097158220 cites W2018407860 @default.
• W3097158220 cites W2021411036 @default.
• W3097158220 cites W2029722851 @default.
• W3097158220 cites W2031473606 @default.
• W3097158220 cites W2035259525 @default.
• W3097158220 cites W2045513798 @default.
• W3097158220 cites W2046812072 @default.
• W3097158220 cites W2047608066 @default.
• W3097158220 cites W2051980021 @default.
• W3097158220 cites W2052782728 @default.
• W3097158220 cites W2054450921 @default.
• W3097158220 cites W2055228524 @default.
• W3097158220 cites W2058476300 @default.
• W3097158220 cites W2058484243 @default.
• W3097158220 cites W2059619755 @default.
• W3097158220 cites W2061554699 @default.
• W3097158220 cites W2064855628 @default.
• W3097158220 cites W2066758446 @default.
• W3097158220 cites W2066777748 @default.
• W3097158220 cites W2074421032 @default.
• W3097158220 cites W2087481500 @default.
• W3097158220 cites W2091083791 @default.
• W3097158220 cites W2093770528 @default.
• W3097158220 cites W2094190365 @default.
• W3097158220 cites W2098733695 @default.
• W3097158220 cites W2105092978 @default.
• W3097158220 cites W2106285196 @default.
• W3097158220 cites W2108864389 @default.
• W3097158220 cites W2110569728 @default.
• W3097158220 cites W2116692433 @default.
• W3097158220 cites W2120357482 @default.
• W3097158220 cites W2120831575 @default.
• W3097158220 cites W2122904975 @default.
• W3097158220 cites W2125245370 @default.
• W3097158220 cites W2126763861 @default.
• W3097158220 cites W2128409425 @default.
• W3097158220 cites W2131476866 @default.
• W3097158220 cites W2131554146 @default.

• next